Therapy Analysis and Evidenced-Based Treatment Guidelines (Including Review of Antiviral Medications)
|
|
- Dina Shaw
- 5 years ago
- Views:
Transcription
1 Therapy Analysis and Evidenced-Based Treatment Guidelines (Including Review of Antiviral Medications) Jason Smith, PharmD ABSTRACT OBJECTIVE: To summarize current treatment options and guidelines for treatment of HBV infection and HIV-HBV co-infection, including a review of the relevant antiviral agents. SUMMARY: Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection have caused large global epidemics, which may overlap because they are transmitted by similar routes, including sex and injection drug use. About 30% of individuals with chronic HBV infection develop cirrhosis, and 5% to 10% develop hepatocellular cancer (HCC). In HBV-HIV co-infection, HIV decreases the rate at which hepatitis B E antigen (HBeAg) is lost, increases levels of HBV DNA, and increases the progression to cirrhosis, the number of liver-related complications, and mortality. Three classes of oral antiviral agents for HBV are approved in the United States. L-nucleoside analogs include lamivudine, emtricitabine, and telbivudine. Acyclic adenine phosphonates are adefovir and tenofovir, which is not yet approved for HBV infection. Entecavir is a guanine nucleoside analog. HBV resistance to antiviral agents arises because of HBV s rapid viral production and the high rate of spontaneous mutations. Anti-HBV therapy is also effective in patients with HIV-HBV co-infection. The decision to treat HBV in a patient with HIV-HBV co-infection depends on whether highly active antiretroviral therapy (HAART) for HIV is indicated, the severity of the liver disease, the likelihood of response, and the potential for adverse events. CONCLUSION: Effective treatment of HBV infection is important to reduce risk of cirrhosis, HCC, and death. Treatment of HBV infection in HIV-infected persons should consider the activity of the antiviral agents used against both viruses. J Manag Care Pharm. 2008; 14(5):S7-S11 Copyright 2008, Academy of Managed Care Pharmacy. All rights reserved. Author JASON SMITH, PHARMD, is a clinical pharmacist, Gastroenterology and Hepatology, at the Veterans Affairs Greater Los Angeles Healthcare System. AUTHOR CORRESPONDENCE: Jason Smith, PharmD, Clinical Pharmacist, Gastroenterology and Hepatology, Veterans Affairs Greater Los Angeles Healthcare System, Wilshire Blvd. 111C, Los Angeles, CA Tel.: , Ext ; Fax: ; jason.smith2@va.gov Background on HIV and HBV Human immunodeficiency virus (HIV) infection and hepatitis B virus (HBV) infection, which overlap since they are transmitted by similar routes, including sex and injection drug use, have caused large global epidemics. HIV, a retrovirus with an RNA genome that has 2 variants (HIV-1 is most common in the United States), targets CD4 cells and damages the host immune system. HBV, a hepadnavirus with a DNA genome that has 8 genotypes, targets liver cells (hepatocytes), and also damages the host immune system. HBV is 50 to 100 times more infectious than HIV. 1,2 While the tests (HIV-1 RNA viral load and CD4 cell counts) and clinical course for HIV infection are somewhat straightforward, the tests and clinical course for HBV are more complex. Chronic HBV infection is characterized by changes in HBV viral load (usually represented by viral counts in log units). Several tests measure HBV viral load and activity. The following are typical tests used to measure HBV viral load: 3 Serum HBV DNA levels, measured in log units Serum HBV DNA is present at measurable levels during acute infection, but may or may not be detected during chronic infection or during reactivation in hepatitis B E antigen (HBeAg)-negative chronic hepatitis. Alterations in liver function reflected in alanine transaminase (ALT) levels Various HBV-specific antigens and antibodies to them, measured in log units HBeAg, a peptide normally detectable in the bloodstream when the hepatitis B virus is actively reproducing, associated with increased infectiousness and greater risk of progression to liver disease, is used clinically as a measure of viral replication, infectivity, and severity Antibody to HBeAg (anti-hbeag) is used clinically as a marker for reduced replication Surface antigen (HBsAg) and antibody to core antigen (anti- HBc) are markers of both acute and chronic infection. The progression of HBV disease after acute infection is very high (>90%) in children, but very low (<5%) in immunocompetent adults. 4,5 About 30% of individuals with chronic HBV infection develop cirrhosis, and 5% to 10% develop hepatocellular cancer (HCC). 4 About one fourth of patients with cirrhosis decompensate and develop liver failure within 5 years. 6 Chronic HBV infection is the sixth leading cause of liver transplantation in the United States. 7 It should also be noted that the presence of HBV antigen is considered as antigen positive, and lack of antigen is considered antigen negative. Vol. 14, No. 5, S-a June 2008 JMCP Supplement to Journal of Managed Care Pharmacy S7
2 TABLE 1 Management of Antiviral Resistant HBV 8 Resistance Status Therapy Recommended Lamivudine resistant Add adefovir or tenofovir Stop lamivudine, switch to emtricitabine/tenofovir a Stop lamivudine, switch to entecavir (pre-existing lamivudine resistance mutation predisposes to entecavir a resistance) b Adefovir resistance Add lamivudine b Stop adefovir, switch to emtricitabine/tenofovir a Switch to or add entecavira b Entecavir resistance Switch to or add adefovir Switch to or add tenofovir a Telbivudine resistancec Add adefovir Add tenofovir a Stop telbivudine, switch to emtricitabine/tenofovir a Stop telbivudine, switch to entecavir (re-existing telbivudine resistance mutation predisposes to entecavir resistance) Entecavir is not appropriate to treat HIV-HBV co-infected patients unless used with a fully suppressive antiretroviral regimen. 28 a In HIV co-infected persons; scanty in vivo data in non-hiv-infected persons. b Durability of viral suppression unknown, especially in patients with prior lamivudine resistance. c Clinical data not available. Treatment Guidelines for HBV-Infected and HIV-HBV Co-Infected Patients Although many guidelines and consensus statements have been published, the primary source for treatment of patients HBVinfected without HIV co-infection are the American Association for the Study of Liver Diseases (AASLD) 2007 Hepatitis B guidelines. 8 The management of anti-hbv therapy in patients with antiviral-resistant HBV is outlined in the AASLD guidelines (Table 1). 8 The U.S. Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, last updated January 29, 2008, are the preferred guidelines for treatment of HIV-HBV co-infected patients. Antiretroviral therapy (ART) treatment is normally initiated when CD4 counts are less than 350 (Table 2). 9 TABLE 2 Treatment Recommendations for HIV-HBV Co-Infection 9 HIV HBV Recommended Therapies Treatment Treatment Required Not Use either tenofovir/emtricitabine or tenofovir plus required lamivudine as the nucleoside analog backbone of HIV therapy. Do NOT use lamivudine, tenofovir, or emtricitabine as single agents to avoid development of HBV resistance. Required Required Use either tenofovir plus lamivudine or tenofovir/ emtricitabine as the nucleoside analog backbone of HIV therapy. Use of entecavir may be considered in combination with tenofovir, emtricitabine, or lamivudine. Use of adefovir may be considered in combination with emtricitabine or lamivudine; do NOT use tenofovir and adefovir together. Do NOT use lamivudine, tenofovir, or emtricitabine as single agents to avoid development of HBV resistance. Not Required Pegylated interferon does not lead to HIV or HBV required resistance and may be considered. Adefovir may be considered but presents a theoretical risk of development of HIV resistance to tenofovir. AVOID use of emtricitabine, lamivudine, tenofovir, or entecavir without HAART as HIV resistance may emerge. HAART=highly active antiretroviral treatment; HBV=hepatitis B virus; HIV=human immunodeficiency virus. Impact of Co-Infection With HIV and HBV In co-infection, HIV affects HBV disease progression more than HBV affects the course of HIV infection. In molecular terms, HIV decreases the rate at which HBeAg is lost and increases levels of HBV DNA. In clinical terms, HIV increases the progression to cirrhosis, increases the number of liver-related complications, and increases mortality On the other hand, HBV affects HIV disease by activating the immune system and by the HBV-X protein (HBV-X protein stimulates viral genome replication), which may induce HIV replication and transcription, but there is typically no change in CD4 cell count and no evidence for clinical impact of HBV on HIV disease. 15 The decision to treat HBV in a patient with HIV-HBV coinfection depends on whether highly active antiretroviral therapy (HAART) for HIV is indicated, liver disease severity, likelihood of response, and adverse event potential. The goal of HBV therapy is to eradicate the virus (by suppression of HBV DNA to undetectable levels) and to prevent complications of liver disease, including cirrhosis, decompensation, and liver cancer, and finally to reverse chronic carrier state HbsAg/HbsAb seroconversion. Complete response to HBV therapy involves biochemical (serum ALT within normal range), virologic (undetectable serum HBV DNA and loss of HBeAg in HBeAg-positive patients), and histologic improvement. 16 The level of detection of HBV DNA depends on the assay used due to the sensitivity of these assays over wide concentrations. 16 S8 Supplement to Journal of Managed Care Pharmacy JMCP June 2008 Vol. 14, No. 5, S-a
3 HBV Antiviral Therapies While interferon and pegylated interferon have been used to treat HBV infection, 3 additional classes of oral anti-hbv therapy are now available: L-pyrimidine nucleoside analogs, acyclic phosphonates, and a guanosine nucleoside analog. L-nucleoside analogs approved by the FDA include lamivudine, defovir, dipivoxil, and tenofovir disoproxil fumarate, which is approved for use in HIV infection but not yet for HBV infection. Entecavir is a guanine nucleoside analog. A National Institutes of Health (NIH) clinical research workshop estimated the comparative activity of anti-hbv agents on various parameters used to measure response of HBV infection to therapy at 1 year; they used data from various clinical trials. 16 HBeAg-positive patients have a more pronounced decline in HBV DNA in response to therapy than HBeAg-negative patients. 16 Lamivudine was the first oral nucleoside approved for treatment of HBV infection. The other L-nucleosides are similar to lamivudine. While about half of patients who are HBeAg-positive at baseline become HBeAg-negative by 5 years, resistance to lamivudine in HBV emerges relatively rapidly (24% at 1 year, 49% at 3 years, and 69% at 5 years). 17,18 As a result, lamivudine is no longer a first-choice therapy for HBV infection. 8,19 Adefovir is an acyclic phosphonate indicated for HBV but not for HIV infection. An observational cohort followed 35 HIV-HBV co-infected patients resistant to lamivudine for up to 192 weeks. Adding adefovir to ART that included lamivudine was well tolerated and resulted in sustained reductions in both HBV DNA (percentage with <1,000 copies per ml was 6% at 48 weeks, 27% at 96 weeks, 46% at 144 weeks, and 58% at 192 weeks) and ALT (normalization in 14% at 48 weeks, 48% at 96 weeks, 68% at 144 weeks, and 70% at 192 weeks). 20 During therapy for chronic HBV, resistance develops to adefovir over time (3% at 2 years, 11% at 3 years, 18% at 4 years, and 29% at 5 years). 16 Tenofovir is an acyclic phosphonate that is very similar to adefovir indicated for HIV but not HBV, although tenofovir has been shown to inhibit HBV DNA polymerase. Tenofovir has been shown to have activity against both viruses in patients with HBV 21 or co-infected with both HIV and HBV. 22 For example, in a study of 53 patients with high levels (>6 log copies per ml) of HBV DNA, at week 48 the tenofovir-treated patients (n = 35) had decreased 5.5 log units compared with 2.8 log units for adefovirtreated patients (n=18). 21 In another study of 52 co-infected patients on stable ART with HIV viral load <10,000 copies per ml (74% had <50 copies per ml at baseline and 94% lamivudine resistant) and serum HBV DNA 5 log copies per ml or higher (86% HBeAg-positive), tenofovir was not inferior to adefovir without safety issues, and the study was terminated early. 22 Other studies have shown that tenofovir was able to reduce HBV viral load despite resistance to adefovir or lamivudine, and no patients developed viral breakthrough while receiving tenofovir therapy Entecavir is a guanosine analog that inhibits multiple steps in HBV replication without inhibiting human mitochondrial DNA polymerase-γ. Recent data indicated entecavir also has activity TABLE 3 Responses to Anti-HBV Agents in Patients with HIV-HBV Co-Infection 29 Interferon Lamivudine Entacavir Adefovir Tenovir HBe sero- 9% 11% NR 7% 4% conversion HBV DNA NR decline (log units) ALT 12%-20% 30%-50% 49% 35%-66% NR Normalized Histologic NR NR NR 33%-50% NR improvement ALT=alanine transaminase; NR=not reported. Note: These values are comparisons of the results of various clinical trials, and, therefore, should be taken as only a guide to probable relative activity. against HIV and tends to target HIV virus resistant to antiretroviral drugs. 25 Over 3 years, the cumulative rate of resistance to entecavir in treatment-naïve HBV-infected patients was 1.1%. Virologic rebound occurred in 20.6% (14/68) lamivudinerefractory patients treated with entecavir. 26 A recent analysis determined that entecavir would be cost-effective versus lamivudine in the treatment of HBeAg-positive HBV infection. 27 The activity of entecavir in HIV-HBV co-infected patients differs depending on prior exposure to ART. Some studies (although based on small patient numbers) have shown good viral suppression in ART-naïve patients but much less so in ART-experienced patients. 27 Entecavir was shown to target the M184V (methionine to valine at position 184) mutation in the HIV reverse transcriptase gene. 28 Therefore, entecavir is not appropriate to treat HIV-HBV co-infected patients unless used with a fully suppressive antiretroviral regimen. 9 Liver-Related Mortality in Co-Infected Patients The risk of liver-related mortality was estimated in the Multicenter AIDS Cohort Study (MACS) in which about 6% (326/5,293) of the men who had sex with men were HBsAg-positive at baseline. 13 The rate of liver mortality for HIV-HBV co-infected patients was 14.2 deaths/1,000 patient-years compared with 1.7 deaths/1,000 patient-years for HIV-positive, HBV-negative patients and 0.8 deaths/1,000 patient-years for HIV-negative, HBV-positive patients. In MACS, concomitant HIV infection increased the relative risk for liver death from HBV infections 18.7 fold. In the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study that evaluated mortality in 23,441 HIV-infected persons followed for a total of 76,893 patient-years, the relative risk of liver-related death for those with HBV was lower, 3.7 (95% CI= ). 14 Response to Anti-HBV Therapy in Co-Infected Patients Anti-HBV therapy is effective in patients with HIV-HBV coinfection. Data from a summary article published in 2006 prewww.amcp.org Vol. 14, No. 5, S-a June 2008 JMCP Supplement to Journal of Managed Care Pharmacy S9
4 senting a treatment algorithm for HBV in HIV-infected patients are presented in Table The following paragraphs summarize key observations about the response rate of HBV infection in selected clinical studies of HIV-HBV co-infected patients. Interferon-α can be used in co-infected patients but seems to have some complications. A retrospective cohort study followed 144 HBeAg-positive patients (69 HIV-positive) for 45 months. HIV infection was associated with poorer response to interferon-α, more frequent HBV reactivations, and increased incidence of cirrhosis and cirrhosis-related death in cases of low CD4 cell count; however, interferon-α therapy reduced the incidence of HBVrelated cirrhosis regardless of HIV status. 12 Lamivudine appeared effective initially as monotherapy in coinfected patients, but resistance has been shown to develop quickly. In a randomized, controlled study of lamivudine therapy in 1,790 patients, the median decrease in HBV DNA level was 2.0 log units at 12 weeks and 2.7 log units at 52 weeks compared with no decrease in the placebo arm. 30 A retrospective cohort study of 46 co-infected patients treated with lamivudine documented lamivudine resistance of 25% at 1 year and 52% at 2 years. 31 Emtricitabine has been used experimentally in co-infected patients with some evidence of effect. In a double-blind, parallel study of co-infected patients, patients were given emtricitabine 25 mg, 100 mg, or 200 mg once daily for 48 weeks and followed for an additional 48 weeks on open-label 200 mg emtricitabine. Emtricitabine was associated with a mean decrease in HBV level of 3.4 log units at 56 days, which was maintained after 48 weeks of treatment in more than half the patients. 32,33 Entecavir has shown some effect in lamivudine resistant virus. In co-infected patients with the tyrosine-methionine-aspartateaspartate (YMDD) lamivudine-resistance mutation treated with entecavir, the mean decrease in HBV DNA level was 3.66 log units at 6 months, and 84% (57/68) had either an HBV DNA level <400 copies per ml or a 2 log or greater reduction from baseline. 34 Combination therapy with adefovir and ART has been studied in co-infected patients and shown to reduce HBV viral load. For example, when adefovir was added to ART that included lamivudine in 35 co-infected patients with a median baseline HBV DNA level of 9.76 log copies per ml, the HBV DNA level dropped 5.08 log units at 48 weeks, 4.52 at 96 weeks, and 3.86 at 144 weeks, all P<0.001). Of the 29 who completed 144 weeks of therapy, 7 (25%) had HBV DNA levels <2.3 log units. 20 In substudies, patients co-infected with HIV and HBV in the phase III studies of tenofovir therapy for treatment of HIV, there was a difference in response between ART-naïve (substudy 903) and antiretroviral-experienced (substudy 907) patients. 35 In the ART-naïve patients, the mean decrease in HBV DNA at 48 weeks was 4.7 log units for the 5 patients receiving tenofovir and lamivudine compared with 3.0 log units for the 6 patients receiving only lamivudine. In the ART-experienced patients, the mean change in HBV DNA at 24 weeks was a decrease in 4.9 log units for the 10 patients who received tenofovir compared with an increase of 2.1 log units for the 2 patients randomized to receive placebo. Resistance of HBV to Anti-HBV Agents Resistance of HBV to drug treatment arises because of the high rate of viral production (1 to 10 trillion virions per day) combined with the high rate of spontaneous mutations due to the lack of proofreading capacity of the HBV reverse transcriptase, which is necessary to the replication of this DNA virus that contains a singlestranded region in its 3,200 base pair genome. The base substitution rate of 1 in 100,000 means that all possible single-base changes in the HBV DNA are produced many times each day so that antiviral resistance mutations are present prior to therapy. HBV resistance may be characterized as genotypic, viral, or clinical. Genotypic resistance identifies specific mutations in vitro or in vivo using molecular testing. These mutations underlie viral and clinical resistance. Interestingly, the mutations associated with lamivudine, emtricitabine, entecavir, and telbivudine (most commonly M204I/V, that is, a change from methionine to either isoleucine or valine at position 204 in the HBV polymerase gene in the YMDD region), do not overlap with those associated with resistance to adefovir or tenofovir (A181V and N236T). Genotypic testing should be used to confirm viral or clinical resistance. Viral resistance is characterized by an increase in HBV DNA levels by more than 10-fold (>1 log unit) from the lowest level achieved (the nadir) while adherent to therapy. Serum HBV DNA should be monitored frequently every 3 to 6 months during therapy. Clinical resistance is defined by a rise in serum ALT by more than 2-fold (100%) with a simultaneous rise in HBV DNA levels. 16 Resistance may be prevented or reduced by avoiding unnecessary treatment and initiating treatment with an appropriate antiviral agent (one to which the virus is not already resistant) or with combination therapy. Maximizing patient adherence and checking carefully for medication adherence in patients with virologic breakthrough is crucial. Switching to an alternative drug in nonresponders will also minimize emergence of resistance. 8 Summary Treatment of HBV infection reduces risk of liver complications, including cirrhosis and hepatocellular carcinoma, and death. Suppression of serum HBV DNA to the lowest levels achievable is important because HBV disease progression can occur even when HBV DNA levels are less than 10,000 copies per ml, which corresponds to about 2,000 International Units/milliliter (IU per ml). Available antiviral agents may need to be used in combination to achieve this goal, and improving adherence is important. Emergence of resistance to anti-hbv agents is a key consideration. Treatment of HBV infection should be considered in HIV-infected persons using available agents. It is important to consider the activity of the antiviral agents used against both viruses when selecting treatment regimens. S10 Supplement to Journal of Managed Care Pharmacy JMCP June 2008 Vol. 14, No. 5, S-a
5 REFERENCES 1. Block TM, Guo H, Guo JT. Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis. 2007;11(4): Krogstad P. Molecular biology of the human immunodeficiency virus: current and future targets for intervention. Semin Pediatr Infect Dis. 2003;14(4): Servoss JC, Friedman LS. Serologic and molecular diagnosis of hepatitis B virus. Clin Liver Dis. 2004;8(2): Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology. 2000;118(2 suppl 1):S83-S Moyer LA, Mast EE. Hepatitis B: virology, epidemiology, disease, and prevention, and an overview of viral hepatitis. Am J Prev Med. 1994;10 suppl: Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21(1): Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001;33(2): Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2): Erratum in Hepatology. 2007;45(6): U.S. Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (DHHS Guidelines) January 29, Available at GuidelineDetail.aspx?Menultem=Guidelines&Search=Off&GuidelineID=7&Cl assid=1. Accessed April 1, Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis. 2003;23(2): Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24(3): Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology. 2002;123(6): Thio CL, Seaberg EC, Skolasky Jr, R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349): Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med. 2006;166(15): Gómez-Gonzalo M, Carretero M, Rullas J, et al. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. J Biol Chem. 2001;276(38): Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45(4): Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36(6): Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125(6): Keeffe EB, Dieterich, DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States, an update. Clin Gastroenterol Hepatol. 2006;4(8): Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol. 2006;44(1): van Bömmel F, Wünsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B infection. Hepatology. 2004;40(6): Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology. 2006;44(5): van Bömmel F, Trojan J, Wasmuth H, et al. Efficacy of tenofovir DF for the treatment of adefovir resistance. 58th Annual Meeting of the American Association for the Study of Liver Diseases, November 2-6, 2007, Boston, Massachusetts. Abstract Schildgen O, Schewe CK, Vogel M, Däumer M, Kaiser R, Weitner L, et al. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS. 2004;18(17): McMahon M, Jilek B, Brennan T, et al. The anti-hepatitis B drug entecavir inhibits HIV-1 replication and selects HIV-1 variants resistant to ARV drugs. 14th Conference on Retroviruses and Opportunistic Infections February 25-28, 2007, Los Angeles, California. Abstract LB Colonno RJ. Assessment at 3 years shows high barrier to resistance is maintained in entecavir treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refactory patients. 57th Annual Meeting of the American Association for the Study of Liver Diseases, October 27-31, 2005, Boston, Massachusetts. Abstract Yuan Y, Iloeje UH, Hay J, Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm. 2008;14(1): Available at: data/jmcp/jmcpmaga_janfeb%2008_ pdf 28. Audsley J, Sasadeucz J, Mijch A, et al. The anti-hiv activity of entecavir: serum HIV RNA decreases and selection of M184V mutation occurs in both ART-naïve and -experienced HIV/HBV-co-infected individuals. 15th Conference on Retroviruses and Opportunistic Infections February 3-6, 2008, Boston, Massachusetts. Abstract Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients. J Hepatol. 2006;44(1 suppl):s90-s Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virusco-infected persons in a randomized, controlled study (CAESAR). J Infect Dis. 1999;180(3): Wolters LM, Niesters HG, Hansen BE, et al. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol. 2002;24(3): Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS. 2005;19(3): Erratum: AIDS. 2005;19(6):3 p following Gish R, Leung N, Wang C, et al. Antiviral activity, safety and incidence in chronically infected hepatitis B patients (CHB) given once daily emtricitabine for 2 years. In: Program and abstracts of the 53rd Annual Meeting of the American Association for the Study of Liver Diseases, November 1-5, 2002, Boston, Massachusetts. Hepatology. 2002;36:372A. 34. Pessoa W, Gazzard B, Huang A, et al. Entecavir in HIV/HBV-co-infected patients: safety and efficacy in a Phase II study (ETV-038). 12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005, Boston, Massachusetts. Abstract Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil funarate in ART-naive and -experienced patients co-infected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189(7): Vol. 14, No. 5, S-a June 2008 JMCP Supplement to Journal of Managed Care Pharmacy S11
hepatitis B virus B 15% 25 HBsAg B HBV HBsAg 15% 20% HBV HBV 90% 16 HIV HBV
hepatitis virus HV 20 15% 25 20 30 HV HsAg 3 5 100 HV 15% 20% HV HsAg HV HV HV 90% 16 5% HV 10 59 http://www.aids-care.org.tw HV CD8 73% 98% HV 90% HV HsAg 6 10% HsAg 0.5% 1% HV HV HV HV HCV TNF- TNF-
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationSupplement June 2008 Vol. 14, No. 5, S-a Continuing Education Activity
Reporting the Evidence for Optimal Treatment Options and Formulary Management: Antiviral Drugs in HIV and Hepatitis B Schumarry H. Chao, MD, MBA Jason Smith, PharmD Ian R. McNicholl, PharmD, BCPS William
More informationOur better understanding of the natural
TREATMENT OF CHRONIC HEPATITIS B: MASTERING THE BASICS ON A COMPLEX TOPIC Ke-Qin Hu, MD* ABSTRACT The availability of newer antiviral agents, as well as comprehensive treatment recommendations, has equipped
More informationDual Therapy for Chronic Hepatitis B Virus
Dual Therapy for Chronic Hepatitis B Virus Hussien Elsiesy, MD, and Douglas Dieterich, MD Corresponding author Douglas Dieterich, MD Division of Liver Diseases, Mount Sinai School of Medicine, One Gustave
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationProfessor Vincent Soriano
Five Nations Conference on HIV and Hepatitis in partnership with Professor Vincent Soriano Hospital Carlos III, Madrid, Spain Professor Vincent Soriano in partnership with Hospital Carlos III, Madrid,
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationConsiderations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection
Considerations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection Mahnaz Arian, MD Assistant Professor in infectious Disease Mashhad university of Medical
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationChronic Hepatitis B - Antiviral Resistance in Korea -
Chronic Hepatitis B - Antiviral Resistance in Korea - Young-Suk Lim University of Ulsan College of Medicine Asan Medical Center Seoul, Korea HBV Genome partially double-stranded DNA genome about 3200 nucleotides
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationThe natural course of chronic HBV infection can be divided into four, which are not always continuous.
HEPATITIS B Hepatitis B is a major global health problem. The WHO reports that there are 350 million carriers worldwide. This disease is the leading cause of liver cancer in the world and frequently leads
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationDisclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only
Disclaimer Presenter Release are for reactive use by Medical Information only internal learning/educational use only Any unsolicited request from HCP must be forwarded to Medical Information Housekeeping
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More informationViral hepatitis Prevention Board. Clinical aspects of hepatitis B
Viral hepatitis Prevention Board Clinical aspects of hepatitis B Natural History and serological markers acute and chronic hepatitis B Acute hepatitis B Immune response Immunological tolerance Resolution
More informationLandmarks for Prevention and Treatment
HBeAg-positive chronic hepatitis B Why do I treat my patient with a nucleos(t)ide analogue? Dr. Nancy Leung BSc(Lon) MSc(Lon) MBBS(Lon) MD(Lon), FRCP(Lon) FRCP(Edin) FHKCP FHKAM Consultant Physician, Alice
More informationManagement of hepatitis B virus
Journal of Antimicrobial Chemotherapy Advance Access published May 14, 2008 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkn188 Management of hepatitis B virus Nidhi A. Singh and Nancy Reau* Section
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationIs there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain
Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationTreatment Op+ons for Chronic Hepa++s B. Judith Feinberg, MD Project ECHO Jan. 19, 2017
Treatment Op+ons for Chronic Hepa++s B Judith Feinberg, MD Project ECHO Jan. 19, 2017 Treatment of Chronic Hepatitis B can be prevented by vaccinacon (part of infant series since 1992-3) goal of drug therapy
More informationIs there a need for combination treatment? Yes!
18.0.2012 C Hep Meeting Berlin Is there a need for combination treatment? Yes! Florian van Bömmel University Hospital Leipzig Hepatology Section Germany Most patients respond to monotherapy with entecavir
More informationChronic hepatitis B - New goals, new treatment. New England Journal Of Medicine, 2008, v. 359 n. 23, p
Title Chronic hepatitis B - New goals, new treatment Author(s) Lai, CL; Yuen, MF Citation New England Journal Of Medicine, 2008, v. 359 n. 23, p. 2488-2491 Issued Date 2008 URL http://hdl.handle.net/10722/59270
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationcasebasedhepatitis bmanagement Management of Hepatitis B: A Case-based Approach
casebasedhepatitis bmanagement Management of Hepatitis B: A Case-based Approach In order to receive credit for this activity, please complete the post-test by recording the best answer to each question
More informationARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:xxx REVIEW A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update EMMET B. KEEFFE,* DOUGLAS T. DIETERICH,
More informationHepatitis B in HIV Patients. Mamta K. Jain, M.D., M.P.H. UT Southwestern Medical Center
Hepatitis B in HIV Patients Mamta K. Jain, M.D., M.P.H. UT Southwestern Medical Center Learning Objectives Identify tests to diagnoses HBV active infection, resolved infection, and need for immunization
More informationTenofovir as a drug of choice for the chronic hepatitis B treatment
EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationManagement of Hepatitis B & HIV Coinfection: A Clinical Update. Douglas G. Fish, MD Albany Medical College Cali, Colombia March 14, 2008
Management of Hepatitis B & HIV Coinfection: A Clinical Update Douglas G. Fish, MD Albany Medical College Cali, Colombia March 14, 2008 In patients with HIV/HBV co-infection who are HBcoreAb(IgG + IgM)
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationHepatitis B Prior Authorization Policy
Hepatitis B Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationChronic hepatitis B virus (HBV) infection is an important. New and Emerging Treatment of Chronic Hepatitis B
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:285 294 New and Emerging Treatment of Chronic Hepatitis B EMMET B. KEEFFE* and PATRICK MARCELLIN *Division of Gastroenterology and Hepatology, Stanford University
More informationJ.C. WANG, L.L. HE, Q. CHEN 1. Introduction. Abstract. BACKGROUND: Either combination. European Review for Medical and Pharmacological Sciences
European Review for Medical and Pharmacological Sciences Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation
More informationThe Goal of HBV Therapy. Key Points. The Twin Pillars of HBV Therapy
How to Follow Once You tart Hepatitis B Treatment And When To Worry About esistance American College of Gastroenterology October 16, 21 ra Jacobson, MD Vincent Astor Professor of Medicine Chief, Division
More informationINDIAN JOURNAL OF MEDICAL SPECIALITIES 2010;1(2):97-105
INDIAN JOURNAL OF MEDICAL SPECIALITIES 2010;1(2):97-105 Review Article Approach to Chronic Hepatitis B Virus Infection Pankaj Tyagi, Pankaj Jain, Amit Mishra Abstract Hepatitis B virus (HBV) is one of
More informationViral hepatitis in reproductive health. Pierre Jean Malè. Training in Reproductive Health Research - Geneva 2006
Viral hepatitis in reproductive health Pierre Jean Malè Training in Reproductive Health Research - Geneva 2006 15.03.2006 HBV and HCV treatment Pierre-Jean Malè MD 15.03.2006 Global Impact of Hepatitis
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis B Drug: Baraclude (entecavir), Epivir (lamivudine), Hepsera (adefovir), Intron A (interferon alfa- 2b), Pegasys (peginterferon alfa-2a), Tyzeka (telbivudine),
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationDynamics of HBV DNA Levels, HBV Mutations and Biochemical Parameters during Antiviral Therapy in a Patient with HBeAg-Negative Chronic Hepatitis B
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2007) 25: 183-188 CASE REPORT Dynamics of HBV DNA Levels, HBV Mutations and Biochemical Parameters during Antiviral Therapy in a Patient with HBeAg-Negative
More informationA Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update
Accepted Manuscript A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update Paul Martin, MD, Daryl T.-Y. Lau, MD, MSc, MPH, Mindie H. Nguyen, MD,
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationHepatitis B virus infection (HBV) is global epidemic. Current Treatment Strategies for the Management of Chronic Hepatitis B CHRONIC HEPATITIS B
CHRONIC HEPATITIS B Current Treatment Strategies for the Management of Chronic Hepatitis B Case Study and Commentary, Robert J. Wong, MD, and Walid S. Ayoub, MD ABSTRACT Objective: To review current treatment
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationAntiviral Therapy 2012; 17: (doi: /IMP1945)
Antiviral Therapy 2012; 17:387 394 (doi: 10.3851/IMP1945) Original article HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationNeed for long-term evaluation of therapy in Chronic Hepatitis B
Need for long-term evaluation of therapy in Chronic Hepatitis B VHPB meeting Budapest 18/03/2010 Solko Schalm & Mehlika Toy Licensed Therapy Chronic hepatitis B Drug Date of Efficacy Disease Clinical Mortality
More informationHepatitis C & HIV Coinfection and Brief Advances on Hepatitis B & HIV: The Evidence and New Proposals
Hepatitis C & HIV Coinfection and Brief Advances on Hepatitis B & HIV: The Evidence and New Proposals Douglas G. Fish, MD Albany Medical College April 3, 2009 Cali Colombia Objectives HCV Epidemiology
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationHEPATITIS B: are escape mutants of concern?
VACCINATION: AN EVOLUTIONARY ENGINE FOR SPECIES? Fondation Mérieux Conference Centre Veyrier-du-Lac, France November 25-27, 2013 HEPATITIS B: are escape mutants of concern? Alessandro ZANETTI Department
More informationResponse-guided antiviral therapy in chronic hepatitis B: nucleot(s)ide analogues vs. pegylated interferon
Response-guided antiviral therapy in chronic hepatitis B: Sang Hoon Ahn, M.D., Ph.D. Department of Internal Medicine, Yonsei University College of Medicine, Institute of Gastroenterology, Liver Cirrhosis
More informationHBV/HCV COINFECTIONS IN PATIENTS WITH HIV. Dr Reena Harania MBBS, MRCP, MSc Infectious Disease
HBV/HCV COINFECTIONS IN PATIENTS WITH HIV Dr Reena Harania MBBS, MRCP, MSc Infectious Disease Adults and children estimated to be living with HIV as of end 2005 North America 1.2 million [650 000 1.8 million]
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationHepatitis B in Africa: Epidemiology, Pathophysiology and Challenges
Gilead-sponsored symposium at the 11th INTEREST Workshop 2017 Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges Ponsiano Ocama Department of Medicine Makerere University College of Health
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationGAZETTE COMMON GROUND. CHB: A significant and prevalent disease in the US and worldwide. Inside. Screening, diagnosis, and evaluation
VOL III/III COMMON GROUND GAZETTE Inside CASE 1: Screening, diagnosis, and evaluation P. 1 CASE 2: Initiating treatment P. 4 CASE 3: Managing antiviral resistance P. 5 CASE 4: Achieving the maximum effect
More informationChronic HBV Management in 2013
Chronic HBV Management in 2013 Mohammad Hossein Somi MD Professor of Gastroentrology and hepatology Liver and Gastrointestinal Disease Research Center Tabriz University of Medical Sciences 1 HBV in 2013
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationPerspective Hepatitis B Virus Infection: What Is Current and New
Perspective Hepatitis B Virus Infection: What Is Current and New Hepatitis B virus (HBV) infection is a lifelong dynamic disease that can be controlled with treatment but cannot yet be cured. Risk of end-stage
More informationAntiviral Therapy 14:
Antiviral Therapy 14:679 685 Original article Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy Man-Fung Yuen 1 *,
More informationClinical Policy: Hepatitis B Drugs Reference Number: AZ.CP.PHAR.03 Effective Date: Last Review Date: Line of Business: Arizona Medicaid
Clinical Policy: Reference Number: AZ.CP.PHAR.03 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationentecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd
entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationHorizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research
More informationEntecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients
Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients D.J. Tenney 1, K.A. Pokorowski 1, R.E. Rose 1, C.J. Baldick 1, B.J. Eggers 1, J. Fang 1, M.J. Wichroski 1,
More informationEvaluation of the Cost-Effectiveness of Entecavir Versus Lamivudine in Hepatitis BeAg-Positive Chronic Hepatitis B Patients
FORMULARY MANAGEMENT Evaluation of the Cost-Effectiveness of Entecavir Versus Lamivudine in Hepatitis BeAg-Positive Chronic Hepatitis B Patients Yong Yuan, PhD; Uchenna H. Iloeje, MD, MPH; Joel Hay, PhD;
More informationManagement of chronic hepatitis B
Journal of Hepatology 38 (2003) S90 S103 www.elsevier.com/locate/jhep Management of chronic hepatitis B Hari S. Conjeevaram, Anna Suk-Fong Lok* Division of Gastroenterology, University of Michigan Medical
More informationMedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article
DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationChronic Hepatitis B. What every GP should know. Prof Ed Gane NZ Liver Unit
Chronic Hepatitis B What every GP should know Prof Ed Gane Z Liver Unit Case 1 55 Yr old Tonga male»well but dad died of liver cancer»lfts: ALT 85, GGT 60; ALP 75; bilirubin 12 What next? Case 1 55 Yr
More informationIdentification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir
Title Identification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir Author(s) Wong, DKH; Fung, JYY; Lai, CL; Yuen, RMF Citation Hong Kong Medical
More informationTreatment of chronic hepatitis B: Evolution over two decades_
doi:10.1111/j.1440-1746.2010.06545.x REVIEW Treatment of chronic hepatitis B: Evolution over two decades_6545 138..143 Man-Fung Yuen and Ching-Lung Lai Department of Medicine, the University of Hong Kong,
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationPegasys Hepatitis B. Pegasys (peginterferon alfa-2a) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.02 Subject: Pegasys Hepatitis B Page: 1 of 5 Last Review Date: September 18, 2015 Pegasys Hepatitis
More informationTemporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV
Case report Antiviral Therapy 11:647 652 Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV Karsten Wursthorn 1, Peter Buggisch 1,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationUpdate on HIV/HBV Coinfection: Pathogenesis and Treatment
Update on HIV/HBV Coinfection: Pathogenesis and Treatment Marion Peters, md Professor of Medicine and Chief of Hepatology Research University of California, San Francisco, San Francisco, California Summary
More informationCOMPARISON OF HBV RIBONUCLEASE H DOMAIN IN NAÏVE AND DRUG RESISTANT PATIENTS
HBV RIBONUCLEASE H DOMAIN IN PATIENTS WITH DRUG RESISTANT COMPARISON OF HBV RIBONUCLEASE H DOMAIN IN NAÏVE AND DRUG RESISTANT PATIENTS Surachai Amornsawadwattana, Pattaratida Sa-Nguanmoo, Preeyaporn Vichaiwattana,
More informationPros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
Curr Hepatitis Rep (2010) 9:91 98 DOI 10.1007/s11901-010-0041-7 Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B Milan J. Sonneveld & Harry L. A. Janssen
More informationFebruary 8, World Journal of Gastroenterology. Re: ESPS Manuscript No Dear Dr. Qi:
February 8, 2017 World Journal of Gastroenterology Re: ESPS Manuscript No. 32025 Dear Dr. Qi: My co-authors and I respectfully submit the accompanying revised manuscript, Early hepatitis B viral DNA clearance
More information